HCV drugs Sofosbuvir, Daclatasvir show promise as potential
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Using hepatitis C drugs sofosbuvir and daclatasvir in combination with standard care to treat patients with COVID-19 resulted in better 14-day recovery rates and a shorter hospital stay, according to data presented at AIDS 2020.

To assess the effectiveness of the drug combination for moderate or severe COVID-19, researchers gathered data on patients with COVID-19 at four Iranian University hospitals who were given the treatment during the first wave of the epidemic. Patients were randomly assigned to standard care (hydroxychloroquine ± lopinavir/ritonavir) with or without sofosbuvir and daclatasvir.

Of 66 patients assessed in the study, 33 received sofosbuvir and daclatasvir; the rest received the standard of care. Baseline characteristics were similar between the treatment groups.

Results showed that after 14 days, 29 patients (88%) in the sofosbuvir and daclatasvir group reached clinical recovery compared with 22 (67%) in the control group. Patients in the sofosbuvir and daclatasvir group experienced a shorter duration of hospital stay and median time to discharge compared with the control group.

Researchers have already set up a network of randomized trials to test the combination of sofosbuvir and daclatasvir in more than 2,000 patients with COVID-19 in Brazil. Egypt, South Africa and Iran. There are also more than 2,000 set to be enrolled in prevention trials testing the same drug combination.

The preliminary information is really interesting, because we desperately need an antiviral that can be given early on in the course of the disease to prevent individuals from going on to require hospitalization,” researchers said.

Source: https://www.healio.com/news/infectious-disease/20200709/hcv-drugs-sofosbuvir-daclatasvir-show-promise-as-potential-covid19-treatment
Dr. T●●●●z H●●●●●●i and 1 others like this
Like
Comment
Share